2.29 0.00 (0.00%)
After hours: 4:44PM EST
|Bid||2.29 x 800|
|Ask||2.40 x 800|
|Day's Range||2.1200 - 2.3200|
|52 Week Range||2.1200 - 50.5000|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 20, 2018 - Aug 24, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||35.00|
If you want to know who really controls Innovate Biopharmaceuticals, Inc. (NASDAQ:INNT), then you'll have to look at the makeup of its share registry. Large companies usually have institutions as Read More...
Preliminary top-line data from the alcoholic steatohepatitis (ASH) collaboration with Massachusetts General Hospital shows positive effect of larazotide on ethanol-induced.
NEW YORK, NY / ACCESSWIRE / December 17, 2018 / Innovate Biopharmaceuticals and Tenet Healthcare Corporation both had high activity days on Friday despite any news from the companies. While shares of Innovate ...
CORAL GABLES, FL / ACCESSWIRE / December 14, 2018 / The noticeable stock price volatility has been seen during recent weeks of trading. Healthcare stocks and biotechnology companies have generally been a safe haven for market participants over the years. Keeping this in mind, here are some healthcare stocks to watch this month: Premier Health Group, Inc. (OTC:PHGRF) (CSE:PHGI), Generex Biotechnology Corporation (GNBT), Civitas Solutions, Inc. (CIVI), and Innovate Biopharmaceuticals, Inc. (INNT).
NEW YORK, NY / ACCESSWIRE / December 11, 2018 / Several generic drug stocks were falling into the red on Monday, including Teva Pharmaceuticals, after Wall Street learned that a Washington Post report said an antitrust lawsuit brought by states over two drugs in 2016 has expanded into a major probe of alleged price-fixing across the industry. Shares of Innovate Biopharmaceuticals were soaring despite any news from the company. Innovate Biopharmaceuticals, Inc.
-- Announces collaboration in high unmet need Alcoholic Liver Diseases (ALD), including severe alcoholic hepatitis, with novel gut-specific, clinical-stage asset, larazotide.
RALEIGH, N.C., Nov. 26, 2018 -- Innovate Biopharmaceuticals, Inc. (Nasdaq: INNT), a clinical-stage biotechnology company focused on developing novel medicines for autoimmune.
Innovate Biopharmaceuticals, Inc. (INNT), a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases, today reported its third quarter 2018 financial results and key highlights.
Significant effect on gut epithelial integrity, a mechanism thought to be key for bacterial translocation leading to NAFLD and NASH. Innovate plans to launch a clinical.
Innovate Biopharmaceuticals, Inc. (Innovate) (INNT), a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases, today announced it intends to present at the BIO-Europe Conference, Copenhagen 2018 - 24th Annual Partnering Conference. BIO-Europe is one of the largest partnering conferences in Europe and is being held on November 5-7, 2018, at the Bella Center in Copenhagen, Denmark.
Innovate Biopharmaceuticals, Inc. (“Innovate”) (INNT), a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases, today announced it intends to present at the Jefferies 2018 London Healthcare Conference. The conference is being held on November 14-15, 2018. Innovate is a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases.
RALEIGH, N.C., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (INNT), a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases, announced today a potential expanded use for its lead agent, larazotide acetate, with topline preclinical data demonstrating proof-of-concept in an established model of nonalcoholic steatohepatitis (NASH). Innovate intends to launch a clinical program in NASH with a phase 2 trial in 2019. There are currently no treatments for nonalcoholic fatty liver disease (NAFLD) or NASH approved by the FDA. In the study, researchers assessed the effects of larazotide in a preclinical model of NASH that develops from consumption of a specified diet, the DIAMONDTM mouse model. The preclinical model recapitulates NAFLD/NASH in response to a high fat, high sugar Western diet, including insulin resistance, obesity, and dyslipidemia, which parallels human disease progression, including histopathology. Researchers aimed to assess the effects of multiple doses of larazotide on various markers of NASH. In addition, researchers sought to gauge the effects of larazotide on gut integrity, using a highly specific technique measuring epithelial barrier normalization and intestinal permeability. This measure demonstrated with statistically high significance that larazotide at the doses tested had a clear benefit in reducing gut barrier permeability, a known pathological abnormality in chronic liver diseases, specifically NASH. Agents which may prevent this “leaky” barrier to worsen through the progression of NASH are thought to provide a potential advantage in treating this disease. Innovate plans to submit the complete NASH preclinical results for publication at a major upcoming conference/in 2019.
Following Innovate Biopharmaceuticals’ reverse merger with California’s Monster Digital, the company has been busy raising funds for operations.
Innovate Biopharmaceuticals Inc’s (NASDAQ:INNT): Innovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. With the latest financial year loss of -US$11.6m and a trailing-twelve monthRead More...
Investors need to pay close attention to Innovate Biopharmaceuticals (INNT) stock based on the movements in the options market lately.
NEW YORK, NY / ACCESSWIRE / September 4, 2018 / Both Innovate Biopharmaceuticals and TapImmune sprang to life on Friday seeing big gains after the companies announced plans to present at conferences this ...
NEW YORK, NY / ACCESSWIRE / July 17, 2018 / Genetic Technologies saw big gains on news that its breast cancer and colorectal cancer risk assessment tests are on track. Shares of Innovate were headed in the opposite direction on news that the company has filed a securities registration statement amendment with the SEC to issue up to $175 million of new stock and to sell 14 million shares of existing stock. Innovate Biopharmaceuticals, Inc.